Patents by Inventor Patrick Gage

Patrick Gage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
    Patent number: 11149077
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 19, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR
    Publication number: 20190202894
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 4, 2019
    Inventors: Ray CAMPHAUSEN, David FABRIZIO, Martin C. WRIGHT, Patrick GAGE, John MENDLEIN
  • Methods of treating cancer by administering IGF-IR binding molecules
    Patent number: 10221232
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: March 5, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR
    Publication number: 20170190761
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 6, 2017
    Inventors: Ray CAMPHAUSEN, David FABRIZIO, Martin C. WRIGHT, Patrick GAGE, John MENDLEIN
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR
    Publication number: 20150252097
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: March 16, 2015
    Publication date: September 10, 2015
    Inventors: Ray CAMPHAUSEN, David FABRIZIO, Martin C. WRIGHT, Patrick GAGE, John MENDLEIN
  • Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
    Patent number: 8470332
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: June 25, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR
    Publication number: 20100121033
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: November 21, 2007
    Publication date: May 13, 2010
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein